Hims & Hers Health, Inc. (HIMS) NYSE

<p><a href="https://www.hims.com/" target="_blank">Hims & Hers Health Inc</a> (HIMS) stock is up 10% after the FDA announced today that it has reversed its decision to remove the weight-loss drug Tirzepatide from the shortage list. The FDA has allowed compounders to continue manufacturing